23andMe (NASDAQ:ME - Get Free Report) is set to post its quarterly earnings results after the market closes on Tuesday, November 12th.
23andMe (NASDAQ:ME - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($2.80) earnings per share for the quarter. The company had revenue of $40.41 million for the quarter, compared to analysts' expectations of $50.30 million. 23andMe had a negative return on equity of 83.22% and a negative net margin of 317.03%.
23andMe Stock Down 4.1 %
ME stock traded down $0.19 during mid-day trading on Friday, hitting $4.48. 338,096 shares of the company were exchanged, compared to its average volume of 260,667. The firm has a market capitalization of $109.80 million, a P/E ratio of -0.17 and a beta of 1.26. The business has a fifty day simple moving average of $5.87 and a 200-day simple moving average of $7.82. 23andMe has a 12-month low of $4.34 and a 12-month high of $20.40.
Analysts Set New Price Targets
Separately, TD Cowen cut shares of 23andMe from a "strong-buy" rating to a "strong sell" rating in a research report on Wednesday, August 7th.
Read Our Latest Stock Analysis on 23andMe
23andMe Company Profile
(
Get Free Report)
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Featured Articles
Before you consider 23andMe, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 23andMe wasn't on the list.
While 23andMe currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
